8ERR

SARS-CoV-2 Omicron BA.1 spike ectodomain trimer in complex with the S2X324 neutralizing antibody Fab fragment

8ERR の概要

• エントリーDOI: 10.2210/pdb8err/pdb
• EMDBエントリー: 28559
• 分子名称: Spike glycoprotein, S2X324 heavy chain, S2X324 light chain, ... (5 entities in total)
• 機能のキーワード: sars-cov-2 omicron variant, covid-19, spike glycoprotein, fusion protein, neutralizing antibodies, structural genomics, seattle structural genomics center for infectious disease, ssgcid, inhibitor, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2; 詳細
• タンパク質・核酸の鎖数: 9
• 化学式量合計: 510798.35

構造登録者

Park, Y.J.,Seattle Structural Genomics Center for Infectious Disease (SSGCID),Veesler, D. (登録日: 2022-10-12, 公開日: 2022-10-26, 最終更新日: 2024-11-06)

主引用文献

Park, Y.J.,Pinto, D.,Walls, A.C.,Liu, Z.,De Marco, A.,Benigni, F.,Zatta, F.,Silacci-Fregni, C.,Bassi, J.,Sprouse, K.R.,Addetia, A.,Bowen, J.E.,Stewart, C.,Giurdanella, M.,Saliba, C.,Guarino, B.,Schmid, M.A.,Franko, N.M.,Logue, J.K.,Dang, H.V.,Hauser, K.,di Iulio, J.,Rivera, W.,Schnell, G.,Rajesh, A.,Zhou, J.,Farhat, N.,Kaiser, H.,Montiel-Ruiz, M.,Noack, J.,Lempp, F.A.,Janer, J.,Abdelnabi, R.,Maes, P.,Ferrari, P.,Ceschi, A.,Giannini, O.,de Melo, G.D.,Kergoat, L.,Bourhy, H.,Neyts, J.,Soriaga, L.,Purcell, L.A.,Snell, G.,Whelan, S.P.J.,Lanzavecchia, A.,Virgin, H.W.,Piccoli, L.,Chu, H.Y.,Pizzuto, M.S.,Corti, D.,Veesler, D.
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
Science, 378:619-627, 2022

PubMed Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry distinct spike mutations resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters elicit plasma-neutralizing antibodies against Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5, and that breakthrough infections, but not vaccination alone, induce neutralizing antibodies in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1, BA.2, and BA.4/5 receptor-binding domains, whereas Omicron primary infections elicit B cells of narrow specificity up to 6 months after infection. Although most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant-neutralizing antibody that is a strong candidate for clinical development.

PubMed: 36264829
DOI: 10.1126/science.adc9127

実験手法

ELECTRON MICROSCOPY (3.1 Å)